How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Home Infusion Therapy Services Market
- By Therapy Type: Antibiotic Infusion Therapy, Chemotherapy Infusion Therapy, Total Parenteral Nutrition (TPN), Pain Management Infusion Therapy, Hydration Therapy
- By End User: Hospitals, Home Healthcare Agencies, Ambulatory Surgical Centers, Specialty Clinics, Long-term Care Facilities
- By Route of Administration: Intravenous (IV) Infusion, Subcutaneous Infusion, Epidural Infusion, Intramuscular Infusion
- By Service Provider: Specialty Pharmacy Providers, Home Healthcare Providers, Hospital-based Providers, Third-party Infusion Service Providers
- By Product Type: Infusion Pumps, Infusion Sets and Accessories, Infusion Fluids and Medications, Catheters and Needles
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antibiotic Infusion Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Home Infusion Therapy Services Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
End User 5
Route of Administration 4
Service Provider 4
Product Type 4
Companies profiled
CVS Health Corporation (Coram)
Option Care Health Inc.
Baxter International Inc.
Fresenius Kabi AG
B. Braun Melsungen AG
BioScrip
Inc. (now part of Option Care Health)
Lincare Holdings Inc.
Aveanna Healthcare Holdings Inc.
Medline Industries Inc.
Parata Systems LLC
Nipro Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CVS Health Corporation (Coram)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Option Care Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →BioScrip
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (now part of Option Care Health)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Lincare Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Aveanna Healthcare Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Medline Industries Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Parata Systems LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Smiths Medical (part of ICU Medical)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →MediSpray Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →HCR ManorCare (now part of Encompass Health)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Coram CVS Specialty
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,893M by 2033 · 5.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antibiotic Infusion Therapy36.0
- Chemotherapy Infusion Therapy13.6
- Total Parenteral Nutrition (TPN)22.5
- Pain Management Infusion Therapy14.1
- Hydration Therapy13.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$621.8M → $889.0M · 4.6%
Europe$433.4M → $692.7M · 6.0%
Asia Pacific$395.7M → $557.2M · 4.4%
Latin America$245.0M → $343.6M · 4.3%
Middle East and Africa$188.4M → $267.4M · 4.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.452026
5.462027
5.472028
5.482029
5.512030
5.512031
5.532032
5.542033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CVS Health Corporation (Coram)11.9
- Option Care Health Inc.22.5
- Baxter International Inc.10.9
- Fresenius Kabi AG12.2
- B. Braun Melsungen AG10.2
- BioScrip4.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type29.6%
End User16.3%
Route of Administration15.3%
Service Provider13.2%
Product Type25.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe25.2
- Asia Pacific20.3
- Latin America12.5
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CVS Health Corporation (Coram) | 75 | 91 | 85 | 85 | 95 | 81 | 85 |
| Option Care Health Inc. | 68 | 72 | 90 | 92 | 89 | 77 | 81 |
| Baxter International Inc. | 81 | 66 | 81 | 79 | 84 | 83 | 79 |
| Fresenius Kabi AG | 81 | 77 | 57 | 60 | 71 | 71 | 70 |
| B. Braun Melsungen AG | 63 | 64 | 73 | 65 | 68 | 59 | 65 |
| BioScrip | 56 | 66 | 70 | 71 | 50 | 66 | 63 |
| Inc. (now part of Option Care Health) | 60 | 43 | 58 | 62 | 62 | 42 | 55 |
| Lincare Holdings Inc. | 55 | 44 | 60 | 58 | 54 | 60 | 55 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CVS Health Corporation (Coram)
- Option Care Health Inc.
- Baxter International Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CVS Health Corporation (Coram) | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Option Care Health Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Baxter International Inc. | ✓ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Fresenius Kabi AG | ✓ | ◐ | − | ◐ | ✓ | ◐ |
| B. Braun Melsungen AG | ✓ | ✓ | ◐ | ◐ | ◐ | − |
| BioScrip | − | ◐ | ◐ | ◐ | − | ◐ |
| Inc. (now part of Option Care Health) | ◐ | ◐ | ◐ | − | ◐ | − |
| Lincare Holdings Inc. | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CVS Health Corporation (Coram)85
2Option Care Health Inc.81
3Baxter International Inc.79
4Fresenius Kabi AG70
5B. Braun Melsungen AG65
6BioScrip63
7Inc. (now part of Option Care Health)55
8Lincare Holdings Inc.55
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
CVS Health Corporation (Coram)Option Care Health Inc.Baxter International Inc.
Challenger1
Strong scale, closing on the leaders.
Fresenius Kabi AG
Contender2
Focused players with pockets of strength.
B. Braun Melsungen AGBioScrip
Niche2
Specialists in a single segment or region.
Inc. (now part of Option Care Health)Lincare Holdings Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Home Infusion Therapy Services Market — a $181M beachhead inside a $2.38B market.
Beachhead (SOM)$181Mobtainable near-term
Serviceable (SAM)$961Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Antibiotic Infusion Therapy
Best fit — highest urgency & budget in Therapy Type.
Economic buyer76 fit
Chemotherapy Infusion Therapy
Strong fit — clear ROI and a fast path to value.
End user66 fit
Total Parenteral Nutrition (TPN)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel26%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Home Infusion Therapy Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified22%
Evaluation12%
Closed-won8%
$10.6KCAC
$63KLTV
6.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Home Infusion Therapy Services Market is a resilient opportunity — $3.19B by 2033, compounding at 4.4%.
TAM · 2025$2.26Btoday
TAM · 2033$3.19Bforecast
CAGR4.4%2027–2033
Cumulative$24.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.19BTotal addressable market
SAM$1.22BServiceable available market
SOM$268MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.4% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.19BLarge & growingTAM by 2033 at 4.4% CAGR
$1.22BServiceable nowreachable with today’s model
$268MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.49BBear2.9% CAGR
$3.19BBase4.4% CAGR
$4.08BBull5.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Home Infusion Therapy Services Market — a $2.21B market by 2033. Plan: grow share from 6.8% to 14.9%.
Market size · 2033$2.21Btotal addressable
Market CAGR8.4%2027–2033
Target share14.9%from 6.8% today
Revenue ambition$329Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 14.9% | At risk |
| Revenue | $138M | $329M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 29.0% | 38.9% | On track |
| Customer retention | 86.2% | 93.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $39M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Home Infusion Therapy Services Market conversation — a $6.64B market you can size, segment and defend in minutes.
Market size · 2033$6.64Btotal opportunity
Growth5.9%CAGR to 2033
Addressable buyers1,615+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 3 mopayback period
$64K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
CVS Health Corporation (Coram)Option Care Health Inc.Baxter International Inc.Fresenius Kabi AGB. Braun Melsungen AGBioScripInc. (now part of Option Care Health)Lincare Holdings Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Home Infusion Therapy Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Home Infusion Therapy Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hospice Services Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportHost Cell Contaminant Testing Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportHuman DNA Quantification Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportHuman Papillomavirus (HPV) Testing Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportHuman Parainfluenza Viruses Diagnostics Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportHumanized Mice Model Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportHypercholesterolemia Treatment Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportHyperthermia Systems Market
Market size, share, segmentation and regional forecast.
$673M market · 2025 base year
View reportHypocalcaemia Treatment Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportIdiopathic Intracranial Hypertension Treatment Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportImage Guided Dentals Surgery Market
Market size, share, segmentation and regional forecast.
$327M market · 2025 base year
View reportImmune Repertoire Sequencing Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.